BioMarin Pharmaceutical Inc.
BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPSā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$62.03
Price+0.32%
$0.20
1Y
Price
Market Cap
$11.917b
Large
Price/Earnings 3y Avg5y Avg
23.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-101.0%
1y CAGR-22.5%
3y CAGR-13.5%
5y CAGREarnings
$26.785m
-57.2%
1y CAGR+38.6%
3y CAGR+109.2%
5y CAGREPS
$0.14
-57.5%
1y CAGR+37.0%
3y CAGR+106.3%
5y CAGRBook Value
$5.658b
$6.989b
Assets$1.331b
Liabilities$649.466m
DebtDebt to Assets
9.3%
3x
Debt to EBITDAFree Cash Flow
$475.423m
+1005.1%
1y CAGR+316.2%
3y CAGR+351.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company